Olympus and Revival Healthcare Capital will co-found Swan EndoSurgical, a new company dedicated to developing a novel robotic system designed for gastrointestinal (GI) patient care.
For decades, endoscopy—placing a flexible camera into an existing body orifice—has yielded early and accurate diagnoses of conditions such as GI tract cancer. In recent years, specialists, primarily gastroenterologists, have begun performing endoscopic therapeutic procedures, such as cancer resection, by inserting instruments through the endoscope. However, manual endoscopes and their instruments have limitations that make many advanced procedures within the lumen of the GI tract challenging and not widely available globally.
The development of an endoluminal robot, with its ability to maneuver within the GI tract and deploy flexible arms, provides the opportunity for more patients to benefit from safe and effective procedures, potentially avoiding invasive surgery. This innovation allows for the early, safe, and effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. Furthermore, the technology has the potential for application in numerous other disease areas.
Headquartered in the United States, Swan EndoSurgical has assembled a leadership team of industry professionals who will drive technical, clinical, and commercial development of the robotic platform.
